Genome-wide CRISPR knockout screens to identify cellular regulators of LNP-based mRNA vaccines. mRNAs encoding Green Fluorescent Protein (GFP) were in vitro transcribed (IVT) and delivered to knockout ...

Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively with tumors and deliver mRNA therapy with minimal off-target effects.

LNP–mRNA drug products are produced by mixing the nucleic acid drug substance with various lipid components, such as phospholipids, cholesterol, PEG–lipids and ionizable lipids, resulting in a ...

A team of researchers led by Dr. Kim V. Narry, director of the Center for RNA Research at the Institute for Basic Science (IBS), has uncovered a key cellular mechanism that affects the function of ...

How do immune cells strike a balance, unleashing rapid attacks against pathogens or cancer, while avoiding damage to healthy cells? Research into an immune kill switch holds potential for controlling ...

The United States may be losing its edge in mRNA technology­­. The technology, which powered life-saving COVID-19 vaccines and is now rocketing new cancer therapeutics forward, will soon undergo a ...

While the fabled fountain of youth may not actually exist, a new type of therapy now does.

The team applied this method to mRNA/saRNA constructs from 1 to 10 kb and assessed pH ranges from 3 to 6. For all the RNA constructs, the J2 immunoblot signal—a marker for dsRNA strands—decreased with ...